Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer (Q33923405)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 December 2011

Language	Label	Description	Also known as
English	Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer	scientific article published on 19 December 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Geoffrey Buckle

object named as

Geoffrey C Buckle

11

0 references

object named as

David I Quinn

6

0 references

Philip W. Kantoff

object named as

Philip W Kantoff

20

0 references

Mary-Ellen Taplin

18

object named as

Mary-Ellen Taplin

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Toni K Choueiri

1

object named as

Toni K Choueiri

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Robert W Ross

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Susanna Jacobus

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Ulka Vaishampayan

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Evan Y Yu

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Noah M Hahn

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Thomas E Hutson

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Guru Sonpavde

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Stephanie C Morrissey

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

William Y Kim

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Daniel P Petrylak

13

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Christopher W Ryan

14

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Mario A Eisenberger

15

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Amir Mortazavi

16

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Glenn J Bubley

17

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jonathan E Rosenberg

19

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

19 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

507-512

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

randomized experiment

0 references

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Molecular correlates of gefitinib responsiveness in human bladder cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Systemic chemotherapy for advanced bladder cancer: update and controversies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

An overview of targeted treatments in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

The randomization and stratification of patients to clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

5 July 2018

Phase II study of sunitinib in patients with metastatic urothelial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

29 October 2018

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

29 October 2018

Declaration of Helsinki. Ethical principles for medical research involving human subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

29 October 2018

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

29 October 2018

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4104290

29 October 2018

Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls

1 reference

https://pubmed.ncbi.nlm.nih.gov/22184381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/22184381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22184381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22184381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2011.37.7002

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33923405&oldid=1577703282"